Independent clinical study validates Nanologica's new drug carrier material for oral usage

Nanologica's particles are based on silica (SiO2, sand) that has been used in several industries (life-science, food-science, cosmetics) for a considerable amount of time, and amorphous silica compounds are already approved as food additives and in the pharmaceutical pharmacopeia. However, Nanologica's processing of silica particles results in materials with much higher surface areas (over 1000m2/g in some case) in comparison to commercially available silica today.

Nanologica's R&D has spent the last few years researching the toxicological properties of its NLAB-Silica particles both in vitro and in vivo, internally, together with academic partners and with external partners. Their efforts culminated in an animal model study, a necessary step in validating the oral efficacy and toxicology of Nlab-Silicas

The Animal model study was conducted by the external research lab Vivotecnia (Madrid, Spain) and was commissioned by Nanologica's proprietary subsidiary NLAB Bioscience SL (Malaga, Spain). The results demonstrates that Nanologica's particles show no toxicity and that they behave, despite their increased surface, in a similar way to already known silica particles used in the food, pharma and cosmetic industries in terms of toxicology.

"This is a big step towards regulatory approval for Nanologicas Nlab silica as an excipient for the pharmaceutical industry", says Dr.Alfonso Garcia-Bennett, Research Director Nanologica

Nanologica is a leading designer and producer of porous materials. Its range of mesoporous silica materials shows excellent properties to become the next generation of carrier and delivery vehicles for Life Science, Food Science and Cosmetic applications. Nanologica's mesoporous silica based particles are unique due to their large surfaces areas, controlled porosity and controllable surface chemistry which allow them to carry large amounts of cargo active products, for example pharmaceutical drugs, neutraceuticals or cosmetic active products.

"This important validation gives us the green light to exploit our Nlab-Si Carrier materials commercially in our targeted application area of drug delivery, but also to continue our work on the delivery of nutrients and flavour compounds for the food industry", says Dr. Krim Talia, Managing Director

Potential uses of Nanologica's carrier material:

  • The pharmaceutical industry require the use of delivery vehicles in order to improve their mode of formulation (how they are mixed with other components of a final product) improve their shelf-life, thermal or chemical stability; and even determine for how long a pharmaceutical product will be active, known as drug delivery.
  • In the cosmetic industry the use of Nanologica's delivery vehicles can improve the shelf-life of many active natural products which would otherwise be unstable in normal formulations, such is the case of the anti-aging actives based on vitamin A such as retinols.
  • Nanologica's technology promises new exciting products in the food sector, where delivery of flavors and aromas can be tailored to alter, enhance or mask the taste of certain active molecules, potentially reducing the addition of unhealthy sugar content in many neutraceutical products.

####

About Nanologica
Nanologica specializes in developing novel nanoporous materials for use in a range of industries, from photovoltaics to diagnostics and pharmaceuticals. Founded in 2004, we have a strong portfolio of intellectual property in collaboration with leading nanotechnology researchers at Stockholm University and Ångström Laboratory of Uppsala University. Our research into the design and physicochemical characterization of nanostructures is increasingly vital to product development and manufacturing efficiency.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.